Eledon Pharmaceuticals, Inc. SEC filings ELDN
Eledon Pharmaceuticals, Inc. has 614 filings in SEC EDGAR's recent list, going back to Jun 18, 2007. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 18, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 21, 2026 | Jun 18, 2026 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 10, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2025 | Jun 10, 2025 |
| DEFA14A | Additional proxy material | May 30, 2024 | — |
| DEF 14A | Proxy statement | May 30, 2024 | Jul 10, 2024 |
| DEF 14A | Proxy statement | May 1, 2023 | — |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 21, 2022 |
| DEFA14A | Additional proxy material | Apr 29, 2021 | — |
| DEF 14A | Proxy statement | Apr 29, 2021 | Jun 15, 2021 |
| DEFA14A | Additional proxy material | Dec 10, 2020 | — |
| DEF 14A | Proxy statement | Nov 20, 2020 | Dec 18, 2020 |
| PRE 14A | Preliminary proxy statement | Oct 23, 2020 | Oct 23, 2020 |
| DEFA14A | Additional proxy material | Mar 31, 2020 | — |
| DEF 14A | Proxy statement | Mar 31, 2020 | May 12, 2020 |
| PRE 14A | Preliminary proxy statement | Mar 16, 2020 | May 12, 2020 |
| DEFA14A | Additional proxy material | May 15, 2019 | — |
| DEF 14A | Proxy statement | May 15, 2019 | Jul 11, 2019 |
| DEFA14A | Additional proxy material | Apr 30, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 13, 2018 |
| DEFA14A | Additional proxy material | Aug 18, 2017 | — |
| DEF 14A | Proxy statement | Aug 18, 2017 | Sep 28, 2017 |
| DEFA14A | Additional proxy material | Apr 28, 2017 | — |
| DEFM14A | Filing | Apr 7, 2017 | — |
| DEFA14A | Additional proxy material | Feb 3, 2017 | — |
| PREM14A | Filing | Jan 24, 2017 | Jan 23, 2017 |
| DEFA14A | Additional proxy material | Dec 22, 2016 | — |
| DEFA14A | Additional proxy material | Apr 29, 2016 | — |
| DEF 14A | Proxy statement | Apr 29, 2016 | Jun 15, 2016 |
| DEFA14A | Additional proxy material | Apr 30, 2015 | — |
| DEF 14A | Proxy statement | Apr 30, 2015 | Jun 17, 2015 |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELDN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1404281
- Former names
- Eledon Pharmaceuticals, Inc. (until Oct 30, 2026); Novus Therapeutics, Inc. (until Dec 22, 2020); Tokai Pharmaceuticals Inc (until May 4, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.